Injection of Colon Carcinoma Patients with Autologous Irradiated Tumor Cells and Fibroblasts Genetically Modified to Secrete Interleukin-2 (IL-2): A Phase I Study. San Diego Regional Cancer Center, San Diego, California

Human Gene Therapy

Volumn 6, Issue 2, 1995, Pages 195-204

  Sobol, Robert E ^a   Royston, Ivor ^a   Fakhrai, Habib ^a   Shawler, Daniel L ^a   Carson, Colette ^a   Dorigo, Oliver ^a   Gjerset, Ruth ^a   Gold, Daniel P ^a   Koziol, James ^a   Mercola, Dan ^a   Van Beveren, Chuck ^a   Wilson, Darcy ^a  

^a San Diego Regional Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ANTIPYRETIC AGENT; CORTICOSTEROID; FLUOROURACIL; INTERLEUKIN 2; STEROID;

ANAPHYLAXIS; ARTHRALGIA; AUTOTRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CHILL; CLINICAL PROTOCOL; CLINICAL TRIAL; COLON CARCINOMA; COLON RESECTION; EDEMA; FEVER; FIBROBLAST; FOLLOW UP; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENETIC ENGINEERING; HUMAN; HYPOTENSION; IMMUNE RESPONSE; INFLAMMATION; INFORMED CONSENT; INTRAVENOUS DRUG ADMINISTRATION; LYMPHADENOPATHY; MAXIMUM PERMISSIBLE DOSE; MEDICAL INFORMATION; NONHUMAN; PATIENT MONITORING; RASH; RETROVIRUS; REVIEW; SKIN BIOPSY; TOPICAL DRUG ADMINISTRATION; TUMOR BIOPSY; TUMOR CELL;

CELL TRANSPLANTATION; CLINICAL PROTOCOLS; CLINICAL TRIALS, PHASE I; COLONIC NEOPLASMS; FIBROBLASTS; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMAN; INFORMED CONSENT; INTERLEUKIN-2;

EID: 0029101309     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.1995.6.2-195     Document Type: Article

References (18)

1. Gabrilove JL, Jakubowski A. Hematopoietic growth factors: biology and clinical application. Monograph J Natl Cancer Inst. 10:73-77, 1990.
2. Kelso A. Cytokines: structure and function and synthesis. Current Opinion in Immunology 2(2):215-225, 1989.
3. Borden EC, Sondel PM. Lymphokines and cytokines as cancer treatment. Immunotherapy realized. Cancer 65 (3 Suppl):800-814, 1990.
4. Rosenberg SA, Lotze MT, Mule JJ. New approaches to the immunotherapy of cancer. Ann Intern Med 108:853-864, 1988.
5. Lotze MT, Change AE, Seipp CA, et al. High-dose recombinant interleukin-2 in the treatment of patients with disseminated cancer: responses, treatment-related morbidity and histologic findings. JAMA 256:3117-3124, 1986.
6. Pizza G. Viza D. De Vinci C. Paschuchi JM, Busutti L. Bergami T. Intralymphatic administration of interleukin-2 (IL-2) in cancer patients: a pilot study. Cytokine Research 7(1):45-48, 1988.
7. Sama G. Collins J. Figlin R. Robertson R. Altrock B. Abels R. A pilot study of intralymphatic interleukin-2. II Clinical and biological effects. J Biological Response Modifiers 9(1):81-86, 1990.
8. Gandolfi L. Solmi L. Pizza GC, Bertoni F. Muratori R. De Vinci C. Bacchini P. Morelli MC, Corrado G. Intratumoral echo-guided injection of interleukin-2 and cytokine-activated killer cells in hepatocellular carcinoma. Hepato-Gastroenterology 36(5):352-356, 1989.
9. Bubenik J. Viotenok NN, Kieler J. Prassolov VS, Chumakov PM, Bubenikova D. Simova J. Jandlova T. Local administration of cells containing an inserted IL-2 gene and producing IL-2 inhibits growth of human tumors in nu/nu mice. Immunology Letters 19(4):279-282, 1988.
10. Fearon HR, Pardoll DM, Itaya T. Golumbek P. Levitsky HI, Simons JW, Karasuyama H. Vogelstein B. Frost P. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an anti-tumor response. Cell 60:387-403, 1990.
11. Gansbacher B. Zier K. Daniels B. Cronin K. Bannerji R. Gilboa E. Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 172:12171223, 1990.
12. Watanabe Y. Kuribayashi K. Miyatake S. Nishihara K. Nakayama EL, Taniyama T. Sakata TA. Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells.
13. results in reduced tumorigenicity by augmented anti-tumor immunity. Proc. Natl Acad Sci 86:9456-9460, 1989.
14. Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57:503-512, 1989.
15. Hoover HC, Brandhorst JS, Peters LC et al. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol 11:390-399, 1993.
16. Rosenberg SA, Aebersold P. Cornetta K. et al. Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Eng J Med 323:570-578, 1990.
17. Miller AD, and Rosman GJ. Improved retroviral vectors for gene transfer and expression. BioTechniques 7:980, 1989.
18. Sobol RE, Fakhrai H. Shawler DL, Gjerset R. Dorigo O. Carson C. Khaleghi T. Koziol J. Shiftan T. Royston I. Interleukin-2 gene therapy in a patient with glioblastoma. Gene Therapy (In Press).